James Wakefield

887 total citations
26 papers, 626 citations indexed

About

James Wakefield is a scholar working on Physiology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, James Wakefield has authored 26 papers receiving a total of 626 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Physiology, 10 papers in Molecular Biology and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in James Wakefield's work include Nitric Oxide and Endothelin Effects (9 papers), Blood Pressure and Hypertension Studies (4 papers) and Hormonal Regulation and Hypertension (4 papers). James Wakefield is often cited by papers focused on Nitric Oxide and Endothelin Effects (9 papers), Blood Pressure and Hypertension Studies (4 papers) and Hormonal Regulation and Hypertension (4 papers). James Wakefield collaborates with scholars based in United States, India and Canada. James Wakefield's co-authors include G. J. Thorbecke, Mark A. Findeis, Susan M. Molineaux, Michael S. P. Kelley, Christopher C. Arico-Muendel, Mark G. Currie, Howard W. Benjamin, Neil J. Hayward, Wilmin Bartolini and G. Todd Milne and has published in prestigious journals such as The Journal of Experimental Medicine, The Journal of Immunology and Journal of the American College of Cardiology.

In The Last Decade

James Wakefield

24 papers receiving 579 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Wakefield United States	12	236	227	93	89	82	26	626
Kathryn J. Potter Canada	16	418 1.8×	383 1.7×	67 0.7×	70 0.8×	63 0.8×	42	1.2k
Mohamed Bellahcene United Kingdom	16	287 1.2×	604 2.7×	28 0.3×	25 0.3×	96 1.2×	22	986
Francheska Colón‐González United States	12	64 0.3×	307 1.4×	26 0.3×	94 1.1×	33 0.4×	19	596
Maria V. Fawaz United States	12	111 0.5×	231 1.0×	14 0.2×	57 0.6×	34 0.4×	23	529
François Chouinard Canada	14	100 0.4×	142 0.6×	63 0.7×	222 2.5×	88 1.1×	16	659
Sonemany Salinthone United States	14	92 0.4×	257 1.1×	12 0.1×	35 0.4×	121 1.5×	17	588
M. Noppe Belgium	12	69 0.3×	210 0.9×	40 0.4×	20 0.2×	26 0.3×	16	568
Bruna Girardi Italy	16	47 0.2×	236 1.0×	21 0.2×	84 0.9×	48 0.6×	35	761
David Bode Germany	13	316 1.3×	322 1.4×	78 0.8×	53 0.6×	6 0.1×	23	703
Lei-Miao Yin China	16	187 0.8×	337 1.5×	17 0.2×	50 0.6×	108 1.3×	43	770

Countries citing papers authored by James Wakefield

Since Specialization

Citations

This map shows the geographic impact of James Wakefield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Wakefield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Wakefield more than expected).

Fields of papers citing papers by James Wakefield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Wakefield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Wakefield. The network helps show where James Wakefield may publish in the future.

Co-authorship network of co-authors of James Wakefield

This figure shows the co-authorship network connecting the top 25 collaborators of James Wakefield. A scholar is included among the top collaborators of James Wakefield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Wakefield. James Wakefield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hanrahan, John P., Ian H. de Boer, George L. Bakris, et al.. (2020). Effect of Praliciguat, a Once-Daily, Oral Soluble Guanylate Cyclase Stimulator, on Albuminuria in Patients with Diabetic Kidney Disease: A Randomized, Double-Blind, Phase 2 Trial. Journal of the American Society of Nephrology. 31(10S). 351–351. 1 indexed citations

Hanrahan, John P., Ian H. de Boer, George L. Bakris, et al.. (2020). 1073-P: Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Diabetic Kidney Disease. Diabetes. 69(Supplement_1). 1 indexed citations

Hanrahan, John P., Ian H. de Boer, George L. Bakris, et al.. (2020). Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology. 16(1). 59–69. 28 indexed citations

Wakefield, James, Timothy C. Barden, Jenny Tobin, et al.. (2020). Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats. Pharmacology Research & Perspectives. 8(2). e00579–e00579. 6 indexed citations

Hanrahan, John P., Jelena Seferović, James Wakefield, et al.. (2019). An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 63(4). 733–743. 27 indexed citations

Hanrahan, John P., James Wakefield, Phebe Wilson, et al.. (2018). Rapid Dose Escalation Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension. Diabetes. 67(Supplement_1). 1 indexed citations

Hanrahan, John P., Albert T. Profy, Bernard J. Lavins, et al.. (2016). FIRST-IN-HUMAN SINGLE-ASCENDING-DOSE STUDY OF IW-1973, A NEW SOLUBLE GUANYLATE CYCLASE STIMULATOR. Journal of the American College of Cardiology. 67(13). 1284–1284. 3 indexed citations

Tobin, Jenny, Courtney Shea, Adaline C. Smith, et al.. (2015). Concomitant administration of sGC stimulators with common classes of anti-hypertensive agents results in increased efficacy in spontaneously hypertensive rats. BMC Pharmacology and Toxicology. 16(S1). 2 indexed citations

Wakefield, James, et al.. (2014). Metabolism and disposition of MM‐433593, a selective FAAH‐1 inhibitor, in monkeys. Pharmacology Research & Perspectives. 2(5). e00059–e00059. 4 indexed citations

10.

Arico-Muendel, Christopher C., Bruce Belanger, Dennis R. Benjamin, et al.. (2013). Metabolites of PPI-2458, a Selective, Irreversible Inhibitor of Methionine Aminopeptidase-2: Structure Determination and In Vivo Activity. Drug Metabolism and Disposition. 41(4). 814–826. 9 indexed citations

11.

Busby, Robert, Marco M. Kessler, Wilmin Bartolini, et al.. (2012). Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation. Journal of Pharmacology and Experimental Therapeutics. 344(1). 196–206. 112 indexed citations

12.

Johnston, Tom H., Philippe Huot, Susan H. Fox, et al.. (2010). Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson’s Disease. Journal of Pharmacology and Experimental Therapeutics. 336(2). 423–430. 35 indexed citations

13.

Lazarus, Douglas, Matthew Labenski, James Wakefield, et al.. (2008). An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis. Inflammation Research. 57(1). 18–27. 11 indexed citations

14.

Findeis, Mark A., et al.. (2001). Characterization of cholyl-leu-val-phe-phe-ala-OH as an inhibitor of amyloid beta-peptide polymerization. Amyloid. 8(4). 231–241. 23 indexed citations

15.

Findeis, Mark A., Christopher C. Arico-Muendel, Howard W. Benjamin, et al.. (1999). Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization. Biochemistry. 38(21). 6791–6800. 199 indexed citations

16.

Andjelkovic, Anuska V., et al.. (1998). Phagocytosis of beta-amyloid: A possible requisite for neurotoxicity. Journal of Neuroimmunology. 90(1). 32–32. 1 indexed citations

17.

Schoenthaler, Stephen J., et al.. (1991). Controlled trial of vitamin-mineral supplementation on institutional violence and antisocial behavior. Personality and Individual Differences. 12(4). 340–341. 1 indexed citations

18.

Wakefield, James & G. J. Thorbecke. (1968). RELATIONSHIP OF GERMINAL CENTERS IN LYMPHOID TISSUE TO IMMUNOLOGICAL MEMORY. The Journal of Experimental Medicine. 128(1). 153–169. 34 indexed citations

19.

Wakefield, James & G. J. Thorbecke. (1968). RELATIONSHIP OF GERMINAL CENTERS IN LYMPHOID TISSUE TO IMMUNOLOGICAL MEMORY. The Journal of Experimental Medicine. 128(1). 171–187. 23 indexed citations

20.

Wakefield, James, G. J. Thorbecke, Lloyd J. Old, & Edward A. Boyse. (1967). Production of Immunoglobulins and Their Subunits by Human Tissue Culture Cell Lines. The Journal of Immunology. 99(2). 308–319. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact